AIMS The aim of the study was to evaluate functional and anatomical changes after intravitreal bevacizumab (Avastin) in eyes with persistent macular oedema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). METHODS Twenty-nine consecutive eyes with macular oedema secondary to BRVO (21 eyes) or CRVO (eight eyes) were included in a prospective clinical t...

Purpose: To report a rare case of slow progression carotid cavernous fistula (CCF) with central retinal vein occlusion (CRVO).Case summary: A 66-year-old man presented conjunctival injection and proptosis in the right eye. Best-corrected visual acuity was 0.8 0.5 left eye, respectively, vessel enlargement subconjunctival hemorrhage were observed eye on slit lamp examination. Due to suspicion CC...

A 60-year-old woman who had experienced two episodes of amaurosis fugax in her right eye presented with vision loss. Two weeks earlier, at a private clinic, she was diagnosed with impending central retinal vein occlusion (CRVO) of the right eye and received an intravitreal injection of bevacizumab. Two weeks after this injection she was diagnosed with ischemic CRVO. At 11-weeks post-presentatio...

Background: There is no proven treatment for vision loss in central retinal vein occlusion (CRVO). Bevacizumab has been reported in small series with limited followup to have a positive effect in reducing macular edema (CME) and improving vision in central retinal vein occlusion . We report long term results of Bevacizumab in central retinal vein occlusion. Methods: Prospective interventional c...

PURPOSE To investigate clinical, anatomic, and electrophysiologic response after single intravitreal injection of bevacizumab for macular edema attributable to retinal vein occlusion. DESIGN Prospective nonrandomized, interventional case series. METHODS Twenty-one patients with macular edema attributable to vein occlusion received intravitreal injection of bevacizumab 1.25 mg. Nine patients...

We performed a meta-analysis to investigate the association between the Factor V G1691A polymorphism and the risk of retinal vein occlusion (RVO). This analysis included 37 studies involving 2,510 cases and 3,466 controls. Factor V G1691A was associated with an increased risk of RVO in the allele, heterozygote, dominant, and carrier models (PA < 0.001, odds ratios >1), but not the homozygote or...

The authors report a 46-year-old father and 17-year-old son who each presented with unilateral central retinal vein occlusion (CRVO) and bilateral abnormalities of retinal vascular perfusion. The son presented with a nonperfused CRVO in the left eye, developed traction-rhegmatogenous retinal detachment treated with vitreous surgery, and developed prolonged arteriovenous filling in the retina of...

purpose: to compare repeated intravitreal injections of bevacizumab (ivb) with triamcinolone acetonide (ivt) for treatment of acute branch retinal vein occlusion (brvo). methods: this randomized clinical trial included, 86 eyes with recent onset (less than 12 weeks) brvo. participants were randomly assigned to two treatment groups: the ivb group (43 eyes) consisted of patients who received mont...

Background: Isolated metastasis to the optic nerve (ON) and its sheath from breast cancer (BC) without involvement of other ocular structures is extremely rare. However, it a pivotal diagnosis rule out as both sight- life-threatening condition. We report case isolated ON BC presenting with central retinal vein occlusion (CRVO).&#x0D; Case presentation: A 47-year-old woman known metastatic prese...

C entral retinal vein occlusion (CRVO) is second only to diabetic retinopathy as a vascular cause of vision loss.1 Visual morbidity and blindness are most commonly due to macular capillary nonperfusion and persistent macular edema, as well as macular hemorrhage, vitreous hemorrhage, retinal detachment, and neovascular glaucoma.1,2 As the precipitating event in CRVO is thought to be intravascula...